Sunday, November 19, 2017

3D Signatures Announces Brokered Private Placement

Tailwinds' Take: Once funded, expect the good news to roll for 3DS. This company has a unique technology with many opportunities to partner on...

3D Signatures Announces Completion of Stage 3 of Hodgkin’s Lymphoma Test Validation Program

Tailwinds' Take: the first good news for 3DS in a while comes shortly after the arrival of a strategic investor into the Company. Hidden...

3D Signatures Announces Private Placement With Strategic Partner and Prospectus Update

Tailwinds' Take: this is a key endorsement as the Company looks to lock up more financing. Once they are funded, there should be a...

DXD.V: When the Offering Closes. the Stock Likely Pops…

3D Signatures has been trying to raise money for months. To date, they have not been successful. I think that will change soon as...

3D Signatures Advances Hodgkin’s Lymphoma Test

TORONTO, ON (June 8, 2017) − 3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) (the "Company" or "3DS"), is pleased to announce that the clinical trial...

3D Signatures Inc. Reports Third Quarter 2017 Financial Results

Tailwinds' Take: 3DS accomplished a lot this last quarter, but the bigger catalysts should be coming in the second half of this year as...

3-D Imaging of Telomeres Inside Cells Aids Cancer Diagnosis, Treatment

Tailwinds Take: a well written article by David Templeton of the Pittsburgh Post-Gazette that discusses the work of Dr. Sabine Mai in conjunction with...
video

3D Signatures, Diagnostics For Prostate Cancer

3D Signatures is using telomeres to help diagnose many forms of cancer, including prostate. Hear what they're doing in prostate as well as catalysts...

3DS’ Genomic Imaging for Precision Medicine

As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic...

3D Signatures Receives First Prostate Cancer Blood Samples for PRECISE Clinical Trial

Tailwinds' Take: This is a major milestone for 3DS as PRECISE is the first ever large-scale multi-center study focused on men with a clinical suspicion of...

3D Signatures: Disruptive Technology with an Attractive Business Model

At Tailwinds, we are focused on finding future leaders. Companies that fit our model bring new technologies to growing markets. The combination of disruptive...

3D Signatures Announces Relocation to MaRS Discovery District in Toronto

WINNIPEG, Manitoba, April 18, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce that the...
video

3D Signatures: Telomere Technology Explained (Video)

In this short video, understand how 3DS' groundbreaking 3D Telomere Technology uses chromosomal alignments to diagnose multiple diseases.

3D Signatures Announces Appointment of Dr. Kevin Little as Chief Scientific Officer

WINNIPEG, Manitoba, April 11, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce the appointment...

3D Signatures Added to the Tailwinds Select Portfolio

We are adding shares of 3D Signatures (DXD.V) to the Tailwinds Select Portfolio as of the end of March, 2017 at a share price...

3D Signatures Completes Assay Validation for Hodgkin’s Lymphoma Test

Tailwinds' Take: while not a huge milestone, this is another step forward towards full FDA product approval. 3DS is proving, with every positive result,...

3D Signatures’ TeloView™ Software Identifies and Stages Patients With Alzheimer’s Disease From a Cheek...

Tailwinds' Take: One of many potential applications for 3DS's diagnostic abilities. Alzheimer's represents a potential home run market for TeloView™. Announcement of a partner...

3D Signatures Makes Final Patent Payment

WINNIPEG, MB (March 14, 2017) − 3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) (the “Company” or “3DS”), is pleased to announce that it recently made...

3D Signatures Inc. Initiates Hodgkin’s Lymphoma Validation Program

WINNIPEG, MB (February 23, 2017) − 3D Signatures Inc. (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) (the “Company” or “3DS”), is pleased to announce that the validation program...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address